StockNews.AI
CDXC
StockNews.AI
168 days

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

1. ChromaDex reports Q4 2024 sales of $29.1 million, driven by Tru Niagen® growth. 2. Gross margin increased to 62.5%, while admin expenses decreased by $4.4 million.

Earnings
+52.68%Current Return
VS
+1.07%S&P 500
$5.603/04 04:07 PM EDTEvent Start
$8.5503/05 10:39 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The strong sales growth of 37% indicates positive market demand. Historical examples show sustained sales can drive stock prices upward.

How important is it?

The reported earnings and growth metrics are highly relevant to investor sentiment and stock performance.

Why Short Term?

Immediate investor reaction to strong quarterly results usually translates into short-term price movements.

Related Companies

NDAQ:TRUNDAQ:CPBNYSE:PG
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter. Posted strong gross margin of 62.5%, up 150 basis points from 61.0% in the prior year quarter. General and administrative expense decreased $4.4 million, which includes a $3.5 million reversal of previously accrued roy.

Related News